Elevance Health reported Q4 2025 adjusted diluted EPS of $3.33, bringing full-year earnings to $30.29, which included approximately $3.75 per share in favorable nonrecurring items. Operating revenue for the quarter increased 10% year-over-year to $49.3 billion, driven by premium rate adjustments, though total membership declined by approximately 500,000 to 45.2 million due primarily to Medicaid attrition. The company issued 2026 guidance for adjusted EPS of at least $25.50, representing a significant year-over-year decline, characterizing 2026 as a 'year of execution and repositioning' with a focus on margin improvement over volume growth. Key strategic shifts include expecting a trough year in Medicaid with a negative 1.75% operating margin, a deliberate reduction in Medicare Advantage membership in the 'high teens' percentage range to improve margins, and continued disciplined pricing in the Commercial segment. Despite the near-term headwinds, management reaffirmed its long-term algorithm of at least 12% adjusted EPS growth starting in 2027, supported by the diversification of its platform and growth in its Carillon segment.
| Metric | Value | Change |
|---|---|---|
| Q4 2025 Adjusted Diluted EPS | $3.33 | N/A (Quarterly Result) |
| Full Year 2025 Adjusted Diluted EPS | $30.29 | Includes $3.75 per share in nonrecurring items |
| Q4 2025 Operating Revenue | $49.3 billion | +10% year-over-year |
| 2025 Year-End Membership | 45.2 million | -500,000 year-over-year |
| Q4 2025 Benefit Expense Ratio (Medical Loss Ratio) | 93.5% | In line with guidance |
| Full Year 2025 Benefit Expense Ratio | 90.0% | In line with guidance |
| 2026 Adjusted EPS Guidance | At least $25.50 | Down from $30.29 in 2025 |
| 2026 Medicaid Operating Margin Guidance | Approximately -1.75% | Down from prior year (Trough year) |
| 2026 Medicare Advantage Membership Change | Decline in high teens percentage range | Significant decrease driven by portfolio actions |
| 2026 Operating Cash Flow Guidance | At least $5.5 billion | Up from $4.3 billion in 2025 |
Management is executing a decisive portfolio repositioning strategy, prioritizing margin quality over membership volume. This is most evident in the Medicare Advantage business, where the company anticipates a 'high teens' percentage decline in membership but expects 'meaningful margin improvement' to at least 2%. This shift indicates a move away from market share battles towards sustainable profitability, exiting geographies and products (like PPOs) that do not meet return thresholds. This strategic pivot is designed to stabilize earnings volatility and create a higher-quality base for the 2027 growth acceleration.
The Medicaid segment is being managed as a 'trough year' scenario in 2026, with an expected operating margin of negative 1.75%. Management emphasized that rates are lagging elevated acuity and utilization trends, which are running at roughly twice the historical average. The strategic signal here is the urgency to work with state partners on 'program design changes' and rate actions, alongside internal utilization management. The company is preparing for new federal legislation ('One Big Beautiful Bill Act') which may impact eligibility, signaling a proactive approach to regulatory headwinds rather than a reactive one.
Elevance Health continues to invest heavily in its 'Whole Health' strategy and the Carillon platform to drive long-term growth. Despite near-term headwinds from health plan membership declines affecting CarillonRx, the 'Carillon services' segment is showing resilience with 'strong customer demand.' Management highlighted the integration of advanced analytics, AI-enabled capabilities, and the HealthOS platform to improve care coordination and reduce administrative burden. The commitment to have 80% of prior authorizations in real-time by 2027 signals a focus on technological differentiation to improve provider and member experience.
Capital allocation is shifting towards a more conservative posture in the near term, focusing on balance sheet strength and opportunistic share repurchases ($2.3 billion planned for 2026) rather than large-scale M&A. Management explicitly stated that M&A activity would be lower in 2026 as they prioritize integrating recent acquisitions and scaling internal capabilities. This signals a pause in external growth buying to focus on operational execution and maximizing the value of existing assets, particularly within the Carillon and CareBridge integrations.
The 2026 financial outlook represents a significant step down from 2025 performance, with adjusted EPS guidance set at 'at least $25.50' compared to $30.29 in the prior year. This decline is driven by a confluence of negative factors: a deeply negative Medicaid margin (-1.75%), a substantial drop in Medicare membership, and the non-recurrence of $3.75 per share in nonrecurring tax benefits. This magnitude of earnings contraction raises concerns about the company's ability to navigate the current cost trend environment without sacrificing market share.
Medicaid profitability is deteriorating rapidly, with margins expected to plunge to approximately -1.75% in 2026. Management cited 'elevated acuity and utilization' that is outpacing rate increases, which are only expected to be in the 'mid-single-digit percent range.' The reliance on state governments to approve rate increases in a tight budgetary environment introduces significant execution risk and potential for further downside if cost trends remain elevated.
The company is experiencing broad-based membership declines across its risk-bearing segments. Medicare Advantage is expected to drop by a 'high teens' percentage, Medicaid is projected to decline by ~750,000 members, and Commercial risk membership is expected to fall in the 'high single-digit' range. While management frames this as 'disciplined repositioning,' such widespread volume erosion risks permanent market share loss and indicates that Elevance's pricing may be becoming uncompetitive relative to peers or that the 'One Big Beautiful Bill Act' impacts are more severe than anticipated.
Management recalibrated its long-term margin targets downward, setting the enterprise margin target at 5% to 6% and the Health Benefits segment target at 'mid-single-digit' margins. This reset, attributed to a 'more prudent view of the forward environment' and a shift in business mix towards lower-margin ACA business, suggests that the structural profitability of the core insurance business has weakened. This revision undermines the previous investment thesis centered on higher margin expansion and indicates a 'new normal' of lower returns.
Overall: Management conveyed a tone of disciplined resolve and prudent caution, acknowledging a challenging 'dynamic environment' while expressing confidence in their strategic pivot. They were transparent about the near-term pain required to reset the business, particularly regarding the 'trough year' in Medicaid and the deliberate shedding of lower-margin Medicare membership. There was a distinct shift from defending past performance to outlining a clear, albeit difficult, path to future stability and growth.
Confidence: MEDIUM - Management displayed high confidence in their long-term algorithm and the 'embedded earnings power' of the platform, but confidence in the near-term (2026) was tempered by the use of 'prudent assumptions' and the acknowledgment of significant external headwinds like rate lags and policy changes.
Management established guidance of at least $25.50, a decrease from the $30.29 reported in 2025. This guidance assumes the non-recurrence of approximately $3.75 per share in favorable nonrecurring items from the prior year and reflects a 'prudent' view of the business mix and cost trends.
Revenue is expected to decline in the low single-digit percentage range. This is driven by a low double-digit percentage decline in risk-based membership (Medicare, Medicaid, Commercial Risk), partially offset by higher premium yields and growth in the Carillon segment.
Expected to be 90.2%, plus or minus 50 basis points. This reflects a prudent view of cost trends and shifting acuity within the Medicaid population.
Expected to be 10.6%, plus or minus 50 basis points. The company plans to maintain operational discipline while investing to scale Carillon, embed AI capabilities, and simplify the member experience.
Reaffirmed the long-term algorithm of at least 12% adjusted earnings per share growth annually on average over time. Management expects to return to at least this level of growth in 2027, off the baseline of the 2026 earnings.
Hedging & Uncertainty: Management frequently utilized hedging language to frame the 2026 guidance, using terms like 'prudent assumptions,' 'approximately,' and 'at least' to set conservative expectations. Phrases such as 'we expect,' 'we anticipate,' and 'should be' were prevalent when discussing future membership and cost trends, reflecting the uncertainty of the regulatory and utilization environment. For example, Mark Kaye stated, 'We anticipate our Medicaid operating margin for 2026 to be approximately minus 1.75%,' using 'approximately' to provide wiggle room. However, regarding the long-term algorithm, the language was firmer, with Gail Boudreaux stating, 'we remain confident in our long-term algorithm,' showing a distinct split between near-term caution and long-term conviction.
2026 is a year of execution and repositioning. - Gail Boudreaux, President and CEO
Affordability remains the central challenge in health care. - Gail Boudreaux, President and CEO
We continue to view 2026 as a trough year. - Gail Boudreaux, President and CEO
The outlook we provided today reflects prudent achievable assumptions. - Gail Boudreaux, President and CEO
We are entering 2026 with prudent planning assumptions, focused execution, and targeted investments. - Gail Boudreaux, President and CEO
We are acting decisively in the areas within our control to strengthen margins, reduce volatility, and improve the consistency of our performance. - Gail Boudreaux, President and CEO
Our priority here... is to maintain balance sheet strength and strong credit profile. - Mark Kaye, CFO
Analyst Sentiment: Analysts exhibited a mix of skepticism and concern, particularly regarding the magnitude of the membership declines in Medicare and the depth of the Medicaid losses. Questions from firms like UBS, Barclays, and Wolfe Research focused heavily on the sustainability of margins and the specific drivers of the elevated cost trends. There was a clear focus on understanding whether the headwinds were cyclical or structural.
Management Responses: Management responses were generally direct and data-driven, though they frequently reverted to the 'disciplined repositioning' narrative to explain away volume losses. They were transparent about the negative Medicaid margins but emphasized that 2026 was a planned 'trough year.' When pressed on the long-term algorithm, Gail Boudreaux provided a robust defense, citing multiple independent levers for growth.
Medicare Advantage Membership & AEP Results: Analysts sought to understand the 'high teens' membership decline. Management clarified that this was a deliberate exit from lower-margin PPO products and specific geographies to improve the quality of the book, expecting margin improvement to at least 2%.
Medicaid Rates & Sustainability: There was significant focus on the negative 1.75% margin guidance. Management explained that rates are lagging 'mid-single-digit' cost trends and that they are working with states on program design changes to bridge the gap long-term.
Cost Trends: Analysts asked if 2026 cost trends would improve. Management indicated that while Medicaid trends might moderate slightly from 2025 levels, they remain elevated, and ACA trends are expected to accelerate due to the expiration of subsidies.
Carillon Growth & Margins: Questions centered on how Carillon is performing amidst health plan headwinds. Management highlighted strong external growth (60% in services, 20% in Rx) but noted that internal affiliated membership declines are masking the true performance.
Long-Term Algorithm Confidence: Analysts questioned the confidence in the 12%+ growth target for 2027 given recent underperformance. Management pointed to the 'prudent' nature of the 2026 guidance, suggesting there is upside potential if execution improves.
Elevance Health is in the midst of a painful but necessary transition, sacrificing near-term volume and earnings to reset its risk profile and stabilize margins. The 2026 guidance for a decline in EPS to $25.50, driven by a trough in Medicaid (-1.75% margin) and a mass exodus from Medicare Advantage, creates a challenging investment horizon for the next 12 months. While the 'repositioning' narrative is logical—exiting unprofitable business to improve the quality of revenue—the execution risk is high, particularly regarding the ability to negotiate better Medicaid rates and successfully integrate Carillon to offset insurance declines. The company's quality remains high due to its diversified platform and leading market position, but the business model is facing structural headwinds from elevated utilization trends and regulatory pressure that have forced a downward revision of long-term margin targets to mid-single digits. Critical factors for success include (1) stabilization of Medicaid utilization, (2) successful margin expansion in Medicare to the guided 2%+, and (3) sustained double-digit growth in Carillon's external business. Investors should monitor the medical loss ratio closely in 2026 for signs that the 'prudent' assumptions are holding. While the 12% growth target for 2027 offers a potential catalyst, the current valuation must be weighed against the significant earnings reset and the risk that the 'trough' could be deeper or longer than management anticipates. Therefore, a HOLD rating is warranted until there is clearer evidence of the inflection point in 2027.
The managed care sector is facing a persistent 'elevated acuity and utilization' environment, with cost trends running roughly twice historical averages in Medicaid. Elevance noted that 'rates lag elevated acuity,' suggesting that the industry-wide pricing cycle is lagging behind the surge in healthcare demand, particularly in behavioral health and high-cost treatment settings. This indicates a broader inflationary pressure within the healthcare system that insurers are struggling to pass on to consumers or state governments immediately.
The Medicare Advance Notice for 2026 was described as 'effectively flat,' which does not keep pace with medical cost trends. This creates a 'real pressure on benefit stability' for the entire Medicare Advantage industry. Management's commentary suggests that the current regulatory environment is hostile to MA profitability, potentially forcing industry-wide consolidation or benefit reductions as funding fails to match the complexity and needs of an aging population.
The expiration of enhanced premium subsidies is creating volatility in the Individual ACA market. Elevance noted that they expect 'healthier members to exit' and the remaining population to become 'more acute.' This signals a potential deterioration of the risk pool across the industry in 2026, which could lead to further premium increases or insurer exits from the exchanges if not adequately addressed by risk adjustment mechanisms.